medi1191 with durvalumab in advanced solid tumors
Published 1 year ago • 58 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
2:49
first-in-human trial of medi1191 plus durvalumab in patients with advanced solid tumors
-
5:15
efficacy and safety of medi1191 in patients with solid tumors and superficial lesions
-
0:47
activating the tme with medi1191, a lipid nanoparticle with mrna encoding il-12
-
0:29
safety of continued dosing of medi1191
-
4:54
mgc018 in patients with advanced solid tumors
-
1:32
new advanced solid tumors clinical trial: amg 193 for advanced mtap-null solid tumors
-
2:39
tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma
-
3:07
the use of durvalumab in locally advanced nsclc
-
1:24
durvalumab: the new standard of care for nsclc?
-
1:24
a phase i/ii trial to preliminary efficacy of bnt142 in prospectively confirmed cldn6 solid tumors
-
1:27
new solid tumors clinical trial: bms-986315 for solid tumors, advanced solid tumors
-
0:52
next steps for cabozantinib plus durvalumab in gi cancer
-
2:51
therapeutic challenges for cholangiocarcinoma
-
2:34
dr. langer on practice-changing pacific data in stage iii nsclc
-
1:40
safety results from phase 3b strong trial of durvalumab in patients with urinary tract carcinoma
-
1:00
trial of durvalumab for bladder cancer
-
1:00
dr. joshi on durvalumab and radiation therapy in locally advanced urothelial cancer of the bladder
-
4:25
durvalumab tolerability in non–small cell lung cancer
-
1:34
emerald-1: durvalumab, bevacizumab and tace in unresectable hcc